Traws Pharma (TRAW) Competitors $1.24 +0.04 (+3.33%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW vs. ALXO, GDTC, SRZN, TPST, BCAB, CARA, ENLV, OKUR, TENX, and PULMShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include ALX Oncology (ALXO), CytoMed Therapeutics (GDTC), Surrozen (SRZN), Tempest Therapeutics (TPST), BioAtla (BCAB), Cara Therapeutics (CARA), Enlivex Therapeutics (ENLV), OnKure Therapeutics (OKUR), Tenax Therapeutics (TENX), and Pulmatrix (PULM). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. ALX Oncology CytoMed Therapeutics Surrozen Tempest Therapeutics BioAtla Cara Therapeutics Enlivex Therapeutics OnKure Therapeutics Tenax Therapeutics Pulmatrix Traws Pharma (NASDAQ:TRAW) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends. Is TRAW or ALXO more profitable? ALX Oncology has a net margin of 0.00% compared to Traws Pharma's net margin of -62,294.25%. Traws Pharma's return on equity of 0.00% beat ALX Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Traws Pharma-62,294.25% N/A -822.38% ALX Oncology N/A -93.02%-70.67% Does the MarketBeat Community believe in TRAW or ALXO? ALX Oncology received 57 more outperform votes than Traws Pharma when rated by MarketBeat users. CompanyUnderperformOutperformTraws PharmaN/AN/AALX OncologyOutperform Votes5765.52% Underperform Votes3034.48% Do insiders and institutionals have more ownership in TRAW or ALXO? 7.9% of Traws Pharma shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 13.6% of Traws Pharma shares are held by insiders. Comparatively, 33.4% of ALX Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, TRAW or ALXO? Traws Pharma has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Do analysts recommend TRAW or ALXO? ALX Oncology has a consensus target price of $3.30, suggesting a potential upside of 639.91%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts plainly believe ALX Oncology is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has preferable earnings & valuation, TRAW or ALXO? Traws Pharma has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$226K29.27-$18.95M-$32.81-0.04ALX OncologyN/AN/A-$160.80M-$2.47-0.18 Does the media prefer TRAW or ALXO? In the previous week, ALX Oncology had 1 more articles in the media than Traws Pharma. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 0.96 beat ALX Oncology's score of -0.50 indicating that Traws Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Traws Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative SummaryALX Oncology beats Traws Pharma on 10 of the 16 factors compared between the two stocks. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.51M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-0.019.0426.7819.69Price / Sales29.27253.23386.97118.34Price / CashN/A65.8538.2534.62Price / Book0.106.406.744.50Net Income-$18.95M$143.98M$3.23B$248.32M7 Day Performance12.73%1.90%1.49%-0.03%1 Month Performance-24.39%4.01%11.47%12.72%1 Year PerformanceN/A-3.00%16.57%7.38% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma0.9905 of 5 stars$1.24+3.3%N/AN/A$6.51M$226,000.00-0.0117Earnings ReportALXOALX Oncology3.2392 of 5 stars$0.47+7.1%$3.54+659.8%-97.0%$24.88MN/A-0.1640Analyst ForecastGDTCCytoMed Therapeutics1.5896 of 5 stars$2.27-0.4%$5.00+120.3%+2.9%$24.83M$69,501.000.00N/AGap UpSRZNSurrozen2.9921 of 5 stars$7.50-6.3%$38.50+413.3%-24.7%$24.61M$10.66M-0.3080Gap DownTPSTTempest Therapeutics1.9612 of 5 stars$6.73-2.0%$30.00+345.8%-85.6%$24.60MN/A-4.4020Analyst RevisionBCABBioAtla2.012 of 5 stars$0.42-3.2%$6.00+1,333.7%-83.6%$24.44M$11M-0.2560Gap DownCARACara Therapeutics1.2392 of 5 starsN/A$83.52+∞N/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeENLVEnlivex Therapeutics2.07 of 5 stars$1.02+1.7%$10.00+880.4%-34.3%$24.12MN/A-1.0470OKUROnKure Therapeutics2.9271 of 5 stars$1.79-8.2%$32.33+1,706.3%N/A$24.05MN/A-0.15N/AInsider TradeGap DownHigh Trading VolumeTENXTenax Therapeutics2.0791 of 5 stars$5.75+0.7%$18.00+213.0%+67.2%$23.85MN/A-1.089Analyst RevisionPULMPulmatrix0.3646 of 5 stars$6.50+4.2%N/A+206.5%$23.73M$7.81M-2.4620Earnings ReportAnalyst ForecastGap Up Related Companies and Tools Related Companies ALX Oncology Competitors CytoMed Therapeutics Competitors Surrozen Competitors Tempest Therapeutics Competitors BioAtla Competitors Cara Therapeutics Competitors Enlivex Therapeutics Competitors OnKure Therapeutics Competitors Tenax Therapeutics Competitors Pulmatrix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRAW Stock Free TRAW Stock Alerts